Global Protein Therapeutics Market Dominated by Monoclonal Antibodies
One of the biggest opportunity areas in the Protein Therapeutics Market will be in the field of Biogenerics, which is expected to create a multi-billion dollar market in future.
The key findings of the market report include:
- US is the largest market for therapeutic proteins in the world followed by Europe and Japan.
- Insurance reimbursement is a major factor that decides the success of protein therapeutics.
- Growth in protein therapeutic market will create new opportunities for the drug discovery Contract Research Organizations (CROs).
- High expenditure on R&D and high rate of failure in phase-3 clinical trials remains a major challenge for the global protein therapeutics market.
- Until recently, protein therapeutics faced little generic threat; however, this is likely to change in future with regulatory pathways for the approval of generics already present in Europe and Asia and to be introduced in US by 2009.
Most read news
Topics
Organizations
Related link
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous